[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzBXsFRBEJVYGG8Z_1RExe-UlsGkzsQIbNE6ZBnGrpns":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"Aston University",[4],26,false,9,2,3236,1,23,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Dry Eye",4,{"name":18,"count":16},"Dry Eye Syndromes",{"name":20,"count":16},"Meibomian Gland Dysfunction",{"name":22,"count":11},"Eating Behavior",{"name":24,"count":11},"Healthy",{"name":26,"count":11},"Healthy Participants",{"name":28,"count":11},"Myopia Progression",{"name":30,"count":11},"Parkinson Disease",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06163989","Protecting the Eyes of Gamers With Lubricating Eyedrops","2026-12-30","TheaLoz Duo Eyedrop",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,68,95],{"intervention":36,"totalTrials":11,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":58},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":49},[],{"trials":55,"activeCount":49},[],{"trials":57,"activeCount":49},[],{"trials":59,"activeCount":11,"soonestReadout":35},[60],{"nctId":33,"briefTitle":34,"status":61,"phases":62,"primaryCompletion":35,"completion":35,"start":63,"enrollment":64,"conditions":65,"interventions":67},"RECRUITING",[43],"2024-09-01",28,[18,66],"Computer Vision Syndrome",[36],{"intervention":69,"totalTrials":11,"cells":70},"Anti-allergic Medication",{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":79,"NA":93},{"trials":72,"activeCount":49},[],{"trials":74,"activeCount":49},[],{"trials":76,"activeCount":49},[],{"trials":78,"activeCount":49},[],{"trials":80,"activeCount":49},[81],{"nctId":82,"briefTitle":83,"status":84,"phases":85,"primaryCompletion":86,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"NCT01569191","Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis","COMPLETED",[42],"2012-11","2013-02","2012-03",18,[91],"Hypersensitivity",[69],{"trials":94,"activeCount":49},[],{"intervention":96,"totalTrials":11,"cells":97},"Zolpidem",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":113,"PHASE4":115,"NA":117},{"trials":99,"activeCount":49},[],{"trials":101,"activeCount":49},[],{"trials":103,"activeCount":49},[104],{"nctId":105,"briefTitle":106,"status":84,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":64,"conditions":111,"interventions":112},"NCT03621046","Use of Low-dose Zolpidem in Parkinson's Disease",[40],"2019-12-31","2020-01-24","2018-08-20",[30],[96],{"trials":114,"activeCount":49},[],{"trials":116,"activeCount":49},[],{"trials":118,"activeCount":49},[]]